<p>Osgood-Schlatter disease (OSD), also known as tibial tubercle apophysitis, is a traction apophysitis of the tibial tuberosity that disproportionately affects adolescents during periods of rapid skeletal growth (1). First described independently by Robert Osgood and Carl Schlatter in 1903, this condition represents the most prevalent cause of knee pain in the skeletally immature athletic population (3). Despite its self-limiting nature, OSD can result in prolonged symptoms lasting up to 24 months, with approximately 10% of affected individuals experiencing persistent pain into adulthood, particularly with activities such as kneeling. However, conservative management achieves successful outcomes in over 90% of pediatric cases (4). The burden of OSD extends beyond immediate symptomatology. Recent epidemiological data indicate that lower extremity apophysitis can result in pain lasting between 1 and 45 weeks, with potential consequences for physical activity participation during critical developmental periods (7). This is particularly concerning given the established relationship between childhood physical activity and long-term health outcomes. Furthermore, the condition's propensity to affect athletes during peak competitive years raises important considerations for talent development, psychological well-being, and long-term athletic participation. Historically, OSD management has relied heavily on activity modification and symptomatic treatment. However, advances in our understanding of its pathophysiology—particularly the identification of specific biomechanical risk factors and critical developmental windows—have enabled a more nuanced, multidimensional approach to care.</p>